News and Press Releases
Press releases
Theralase® Technology Effective in Virus Inactivation
June 4, 2024 - Theralase's lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed...
0
Theralase® Release’s 1Q2024 Financial Statements
May 30, 2024 - Theralase releases the Company's unaudited interim consolidated 1Q2024 Financial Statements...
0Theralase® Expands Clinical Team
May 2, 2024 - Theralase expands its clinical team with the hiring of two Clinical Research Associates....
0Theralase® Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024 - Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200....
0Theralase® Granted Canadian Cancer Vaccine Patent
April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic...
0
Theralase® Release’s 4Q2023 Interim Financial Statements
March 27, 2024 - Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”)....
0Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) ...
0Theralase® Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson’s Disease
V.TLT | February 12th, 2024 Toronto, Ontario – February 12th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OT...
0Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
V.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQ...
0Theralase® Closes $CAN 1.2 Million Non-Brokered Private Placement
V.TLT | February 5th, 2024 Toronto, Ontario – February 5th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQ...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
